Triple Point Biologics' Metalloproteinase Inhibitors antibody catalog covers the four known human tissue inhibitors of metalloproteinases — TIMP-1, TIMP-2, TIMP-3, and TIMP-4 — produced as rabbit polyclonal antibodies validated for Western blot and immunohistochemistry. The TIMP family comprises secreted glycoproteins that regulate extracellular matrix remodeling by forming tight, non-covalent complexes with active matrix metalloproteinases (MMPs) at stoichiometric ratios approaching 1:1. Each TIMP member carries a conserved N-terminal inhibitory domain responsible for MMP active-site occlusion and a C-terminal domain that mediates MMP-independent interactions, including pro-MMP activation and cell surface binding. The balance between MMP and TIMP activity is a primary determinant of matrix turnover, making these proteins central research targets in fibrosis, tumor invasion, angiogenesis, and cardiovascular remodeling.

Triple Point Biologics has produced proteinase and inhibitor antibodies since 1994. Each TIMP antibody in this catalog is raised in rabbit against recombinant human antigen spanning functionally characterized domains — for example, the TIMP-2 antibody targets residues covering both the N-terminal MMP-inhibitory wedge and the C-terminal hemopexin-binding region — providing specificity across the protein's known interaction surfaces. All four antibodies are validated for Western blot under reducing conditions and IHC on formalin-fixed paraffin-embedded tissue; immunofluorescence validation data are noted per-clone on individual product pages. Cross-reactivity with mouse and rat orthologs is predicted based on sequence identity and is confirmed where experimentally verified. Every TIMP target in this catalog has a corresponding recombinant protein produced in the same laboratory, supporting use as a matched positive control and enabling standardized signal calibration. Full lot-specific validation documentation is available on the Quality and Validation page.

These antibodies are suited for MMP inhibition kinetics, matched-pair co-immunoprecipitation or proximity ligation experiments alongside TPB recombinant MMPs and TIMPs, and cancer or cardiovascular biomarker studies requiring quantitative Western blot or tissue-section localization. For guidance on designing protease–inhibitor binding assays, see the Protease Activity Assays guide and the Protease Inhibitor Screening guide. Researchers using recombinant TIMPs as assay standards are encouraged to consult the Recombinant Protein Positive Controls guide for recommended working concentrations and signal linearity benchmarks.